(ALIT) Alight - Overview
Stock: PLATFORM, BENEFITS, HEALTHCARE
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.07% |
| Yield on Cost 5y | 1.53% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | 84.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 47.7% |
| Relative Tail Risk | -12.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.58 |
| Alpha | -95.61 |
| Character TTM | |
|---|---|
| Beta | 1.446 |
| Beta Downside | 1.406 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.88% |
| CAGR/Max DD | -0.52 |
Description: ALIT Alight January 11, 2026
Alight Inc. (NYSE: ALIT) is a Chicago-based, technology-enabled services firm that delivers the Alight Worklife platform-a cloud-native suite covering benefits administration, healthcare navigation, financial wellbeing, leave-of-absence management, retiree health, and AI-driven analytics. The company also operates a full-service contact center to manage the end-to-end health, wealth, and wellbeing lifecycle for employers and their employees. Founded in 2020, Alight positions itself within the Human Resource & Employment Services sub-industry.
Key metrics (FY 2023): revenue of roughly $1.9 billion, up ~12% YoY, with an adjusted EBITDA margin near 9%, reflecting the scalability of its SaaS and managed-services model. The HR-tech market is expanding at a 9–10% CAGR, driven by rising corporate focus on employee experience and cost-containment in benefits administration. Adoption of AI for claims routing and predictive health analytics is a sector-wide catalyst that Alight leverages to differentiate its platform.
For a deeper quantitative dive, check out ValueRay’s ALIT dashboard to explore the latest earnings estimates and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -2.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 2.54 > 1.0 |
| NWC/Revenue: 7.73% < 20% (prev 10.53%; Δ -2.80% < -1%) |
| CFO/TA 0.06 > 3% & CFO 354.0m > Net Income -2.16b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (528.5m) vs 12m ago -1.37% < -2% |
| Gross Margin: 36.00% > 18% (prev 0.34%; Δ 3566 % > 0.5%) |
| Asset Turnover: 33.15% > 50% (prev 31.58%; Δ 1.57% > 0%) |
| Interest Coverage Ratio: -20.57 > 6 (EBITDA TTM -1.40b / Interest Expense TTM 88.0m) |
Altman Z'' -4.05
| A: 0.03 (Total Current Assets 1.01b - Total Current Liabilities 829.0m) / Total Assets 5.54b |
| B: -0.51 (Retained Earnings -2.83b / Total Assets 5.54b) |
| C: -0.26 (EBIT TTM -1.81b / Avg Total Assets 6.90b) |
| D: -0.79 (Book Value of Equity -2.79b / Total Liabilities 3.53b) |
| Altman-Z'' Score: -4.05 = D |
Beneish M -3.72
| DSRI: 0.93 (Receivables 399.0m/487.0m, Revenue 2.29b/2.61b) |
| GMI: 0.95 (GM 36.00% / 34.15%) |
| AQI: 0.93 (AQ_t 0.75 / AQ_t-1 0.81) |
| SGI: 0.88 (Revenue 2.29b / 2.61b) |
| TATA: -0.45 (NI -2.16b - CFO 354.0m) / TA 5.54b) |
| Beneish M-Score: -3.72 (Cap -4..+1) = AAA |
What is the price of ALIT shares?
Over the past week, the price has changed by +4.58%, over one month by -15.79%, over three months by -31.87% and over the past year by -74.82%.
Is ALIT a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ALIT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.6 | 186.3% |
| Analysts Target Price | 4.6 | 186.3% |
| ValueRay Target Price | 1.1 | -33.8% |
ALIT Fundamental Data Overview February 03, 2026
P/S = 0.3673
P/B = 0.3995
Revenue TTM = 2.29b USD
EBIT TTM = -1.81b USD
EBITDA TTM = -1.40b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = 20.0m USD (from shortTermDebt, last quarter)
Debt = 2.01b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.80b USD (from netDebt column, last quarter)
Enterprise Value = 2.65b USD (840.7m + Debt 2.01b - CCE 205.0m)
Interest Coverage Ratio = -20.57 (Ebit TTM -1.81b / Interest Expense TTM 88.0m)
EV/FCF = 10.89x (Enterprise Value 2.65b / FCF TTM 243.0m)
FCF Yield = 9.18% (FCF TTM 243.0m / Enterprise Value 2.65b)
FCF Margin = 10.62% (FCF TTM 243.0m / Revenue TTM 2.29b)
Net Margin = -94.23% (Net Income TTM -2.16b / Revenue TTM 2.29b)
Gross Margin = 36.00% ((Revenue TTM 2.29b - Cost of Revenue TTM 1.47b) / Revenue TTM)
Gross Margin QoQ = 38.65% (prev 33.33%)
Tobins Q-Ratio = 0.48 (Enterprise Value 2.65b / Total Assets 5.54b)
Interest Expense / Debt = 1.19% (Interest Expense 24.0m / Debt 2.01b)
Taxrate = 21.0% (US default 21%)
NOPAT = -1.43b (EBIT -1.81b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.21 (Total Current Assets 1.01b / Total Current Liabilities 829.0m)
Debt / Equity = 1.00 (Debt 2.01b / totalStockholderEquity, last quarter 2.00b)
Debt / EBITDA = -1.29 (negative EBITDA) (Net Debt 1.80b / EBITDA -1.40b)
Debt / FCF = 7.43 (Net Debt 1.80b / FCF TTM 243.0m)
Total Stockholder Equity = 3.41b (last 4 quarters mean from totalStockholderEquity)
RoA = -31.24% (Net Income -2.16b / Total Assets 5.54b)
RoE = -63.17% (Net Income TTM -2.16b / Total Stockholder Equity 3.41b)
RoCE = -33.49% (EBIT -1.81b / Capital Employed (Equity 3.41b + L.T.Debt 1.99b))
RoIC = -26.32% (negative operating profit) (NOPAT -1.43b / Invested Capital 5.43b)
WACC = 3.98% (E(840.7m)/V(2.85b) * Re(11.24%) + D(2.01b)/V(2.85b) * Rd(1.19%) * (1-Tc(0.21)))
Discount Rate = 11.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.04%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈207.0m ; Y1≈255.3m ; Y5≈434.9m
Fair Price DCF = 20.77 (EV 12.66b - Net Debt 1.80b = Equity 10.86b / Shares 522.8m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -34.18 | EPS CAGR: -14.47% | SUE: -2.76 | # QB: 0
Revenue Correlation: -63.23 | Revenue CAGR: -12.09% | SUE: -0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.11 | Chg30d=-0.002 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=0.58 | Chg30d=-0.013 | Revisions Net=-3 | Growth EPS=+4.8% | Growth Revenue=+1.2%